Science

We have done many years of research to create the Metresponse Services and find ways to help other researchers. Here are a few of our latest publications including the abstracts and links to where you can find the complete article.

Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine

paper image

2017 - Ebru S. Selen Alpergin - Zeinab Bolandnazar - Martina Sabatini - Michael Rogowski - Grazia Chiellini - Riccardo Zucchi - Fariba M. Assadi-Porter

Complex diseases such as polycystic ovary syndrome (PCOS) are associated with intricate pathophysiological, hormonal, and metabolic feedbacks that make their early diagnosis challenging, thus increasing the prevalence risks for obesity, cardiovascular, and fatty liver diseases. To explore the crosstalk between endocrine and lipid metabolic pathways, we administered 3-iodothyr-onamine (T1AM), a natural analog of thyroid hormone, in a mouse model of PCOS and analyzed plasma and tissue extracts using multidisciplinary omics and biochemical approaches. T1AM administration induces a profound tissue- specific antilipogenic effect in liver and muscle by lowering gene expression of key regulators of lipid metabolism, PTP1B and PLIN2, significantly increasing metabolites (glucogenic, amino acids, carnitine, and citrate) levels, while enhancing protection against oxidative stress. In contrast, T1AM has an opposing effect on the regulation of estrogenic pathways in the ovary by upregulating STAR, CYP11A1, and CYP17A1. Biochemical measurements pro-vide further evidence of significant reduction in liver cholesterol and triglyc- erides in post-T1AM treatment. Our results shed light onto tissue-specific metabolic vs. hormonal pathway interactions, thus illuminating the intricacies within the pathophysiology of PCOS. This study opens up new avenues to design drugs for targeted therapeutics to improve quality of life in complex metabolic diseases.
Keywords: 3-iodothyronamine (T1AM), endocrine, lipid metabolism, metabolomics, Nuclear magnetic resonance (NMR) spectroscopy, polycystic ovary syndrome (PCOS), steroidogenesis.

See This Article

NMR metabolomics show evidence for mitochondrial oxidative stress in a mouse model of polycystic ovary syndrome.

paper image

2015 - E.S. Selin - Z. Bolandnazar - D. Butz, M. Tonelli - J. Haviland - W.P. Porter - F. M. Assadi-Porter

Polycystic ovary syndrome (PCOS) is associated with metabolic and endocrine disorders in women of reproductive age. The etiology of PCOS is still unknown. Mice prenatally treated with glucocorticoids exhibit metabolic disturbances that are similar to those seen in women with PCOS. We used an untargeted nuclear magnetic resonance (NMR)-based metabolomics approach to understand the metabolic changes occurring in the plasma and kidney over time in female glucocorticoid-treated (GC-treated) mice. There are significant changes in plasma amino acid levels (valine, tyrosine, and proline) and their intermediates (2-hydroxybutyrate, 4-aminobutyrate, and taurine), whereas in kidneys, the TCA cycle metabolism (citrate, fumarate, and succinate) and the pentose phosphate (PP) pathway products (inosine and uracil) are significantly altered (p < 0.05) from 8 to 16 weeks of age. Levels of NADH, NAD+, NAD+/NADH, and NADH redox in kidneys indicate increased mitochondrial oxidative stress from 8 to 16 weeks in GC-treated mice. These results indicate that altered metabolic substrates in the plasma and kidneys of treated mice are associated with altered amino acid metabolism, increased cytoplasmic PP, and increased mitochondrial activity, leading to a more oxidized state. This study identifies biomarkers associated with metabolic dysfunction in kidney mitochondria of a prenatal gluococorticoid-treated mouse model of PCOS that may be used as early predictive biomarkers of oxidative stress in the PCOS metabolic disorder in women.
Keywords: polycystic ovary syndrome (PCOS); animal model; metabolomics; nuclear magnetic resonance (NMR); oxidative stress; mitochondria

See This Article

3-iodothyronamine: A high potency metabolic hormone and its potential for therapeutic applications. J. of Endocrinology and Diabetes.

paper image

2015 - M. Rogowski - F.M. Assadi-Porter

3-Iodothyronamide (T1AM) is a naturally produced endogenous hormone like molecule. Only recently it has been discovered in the past decade, the proceeding body of research emerging from its initial discovery has revealed a substantial capacity of T1AM as a new potential hormone that affects numerous physiological processes and organs. Initially, it was hypothesized to be a byproduct of Thyroid Hormone (TH) metabolism; however, the current body of evidence suggests that its production and physiological function appear to be uncoupled and dramatically divergent from that of TH. This review summarizes the physiological and biochemical effects of T1AM reported in the literature along with its proposed mechanisms of action and production pathways. The physiological effects of T1AM appear to be dose specific, in some cases exerting opposing effects in the same biological processes. Uptake, storage, and degree of effect appear to be tissue specific as well. From the current body of literature, potential therapeutic applications with T1AM are quite apparent, ranging from sleep/torpidity induction, conferring protection against ischemic injury, and anti-obesogenic by inducing increased metabolic reliance on lipid oxidation. Future research is needed to understand the specific mechanisms of its dose dependent and tissue dependent effects, its mechanism of entry into the cell, its cellular targets, and primary site of production.

See This Article

NMRFAM-SDF: a protein structure determination framework.

paper image

Superimposition of the manual structure (cyan) and automated structure (green) of the protein IscU (D39A)

2015 - M. Dashti, H, Lee, W., Tonelli, M, Cornilescu, G, F. M. Assadi-Porter, Westler, M., Markley, JL.

The computationally demanding nature of automated NMR structure determination necessitates a delicate balancing of factors that include the time complexity of data collection, the computational complexity of chemical shift assignments, and selection of proper optimization steps. During the past two decades the computational and algorithmic aspects of several discrete steps of the process have been addressed. Although no single comprehensive solution has emerged, the incorporation of a validation protocol has gained recognition as a necessary step for a robust automated approach. The need for validation becomes even more pronounced in cases of proteins with higher structural complexity, where potentially larger errors generated at each step can propagate and accumulate in the process of structure calculation, thereby significantly degrading the efficacy of any software framework. This paper introduces a complete framework for protein structure determination with NMR-from data acquisition to the structure determination. The aim is twofold: to simplify the structure determination process for non-NMR experts whenever feasible, while maintaining flexibility by providing a set of modules that validate each step, and to enable the assessment of error propagations. This framework, called NMRFAM-SDF (NMRFAM-Structure Determination Framework), and its various components are available for download from the NMRFAM website ( http://nmrfam.wisc.edu/software.htm ).
Keywords:ADAPT-NMR; ARECA; Automated protein structure determination framework; CASD-NMR; Non-uniform sampling; PINE; PONDEROSA-C/S; Validation

See This Article

NMR-based metabolomics analysis in muscle and serum of middle-aged ovariectomized rats supplemented with 6-month green tea polyphenols.


2015 - Fariba Assadi-Porter - Ebru Selen - ChwanLi Shen

Metabolomics is an important component of system biology complementing genomics, transcriptomis, and proteomics. The project is to determine the effects of 6-month green tea polyphenols (GTP) supplementation on the serum and muscle metabolome in middle-aged ovariectomized (OVX) rats. 39 SD (6-mo-old) rats were sham-operated (n=13) or OVX (n=26). Both sham and OVX animals received no GTP for 6 months. The remaining OVX animals were provided 1.5% w/v GTP in drinking water for 6 months. Endogenous metabolites in serum and muscle were measured using NMR-based metabolomics. Compared to the sham animals, the OVX animals had the following observation in serum: (1) suppressed glucose metabolites and Krebs cycle (decreases in acetate, acetoacetate, acetone, glycerol, glucose, lactate, pyruvate, citrate, succinate and fumarate), (2) altered amino acids metabolites (decreases in alanine, asparagine, glutamine, isoleucine, leucine, valine, tryptophan, lysine, proline, seruine and threonine; increases in glutamate, glycine, phenylalanine and tyrosine), and (3) reduced lipid metabolites (decreases in myo-inositol). The similar trend in serum of OVX animals was also observed in that of muscle of OVX animals. Intriguingly, compared to the OVX animals, 6-month GTP supplementation to the OVX-treated animals reversed the negative impacts of ovariectomy on the middle-aged rats in terms of metabolites of glucose, Kerbs cycle, amino acids, and lipids. The results suggest that chronic GTP supplementation to the OVX animals affects whole-body metabolism, as shown in serum and muscle. Study supported by NIH/NCCAM AT006691.

See This Article

Novel diagnostics of metabolic dysfunction detected in breath and plasma by selective isotope-assisted labeling

paper image

2012    -    Julia A. Havilanda - Marco Tonelli - Dermot T. Haughey - Warren P. Porter - Fariba M. Assadi-Porter

Metabolomics is the study of a unique fingerprint of small molecules present in biological systems under healthy and disease conditions. One of the major challenges inmetabolomics is validation of fingerprint molecules to identify specifically perturbed pathways in metabolic aberrations. This step is crucial to the understanding of buddingmetabolic pathologies and the ability to identify early indicators of common diseases such as obesity, type 2 diabetesmellitus, metabolic syndrome, polycystic ovary syndrome, and cancer. We present a novel approach to diagnosing aberrations in glucose utilization including metabolic pathway switching in a disease state. We used a well-defined prenatally exposed glucocorticoid mouse model that results in adult females with metabolic dysfunction. We applied the complementary technologies of nuclear magnetic resonance spectroscopy and cavity ring-down spectroscopy to analyze serial plasma samples and real-time breath measurements following selective 13C-isotope–assisted labeling. These platforms allowed us to trace metabolic markers in whole animals and identify key metabolic pathway switching in prenatally glucocorticoid-treated animals. Total glucose flux is significantly proportionally increased through the major oxidative pathways of glycolysis and the pentose phosphate pathway in the prenatally glucocorticoid-treated animals relative to the control animals. This novel diagnostics approach is fast, noninvasive, and sensitive for determining specific pathway utilization, and provides a direct translational application in the health care field.

See This Article